Knowledge Hub

Global Hemophilia Drugs Market To Grow At A CAGR Of 4.76% During The Period 2016-2020

Press Release   •   Oct 26, 2016 08:15 EDT has recently announced the addition of a market study “ Global Hemophilia Drugs Market 2016-2020 ”, is a comparative analysis of the global market.

About Hemophilia

Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.

Technavios analysts forecast the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.

The market is divided into the following segments based on geography:




Technavio's report, Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors



CSL Behring

Novo Nordisk


Download The sample Copy Of This Report:

Other prominent vendors

Alnylam Pharmaceuticals

Amarna Therapeutics

Asklepios BioPharmaceutical



Catalyst Bioscience

Chiesi Farmaceutici

Dimension Therapeutics

Emergent BioSolutions

F. Hoffmann-La Roche

Grifols, Kedrion Biopharma


rEVO Biologics

OPKO Biologics

Sangamo Biosciences

Spark Therapeutics

Swedish Orphan Biovitrum

UniQure Biopharma.

Market driver

Focus on prophylactic treatment

For a full, detailed list, view our report

Market challenge

Low diagnosis rate

For a full, detailed list, view our report

Market trend

Increase in technological innovations

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.